Does the GSTP1 rs1695 AG variant reduce GSTP1 activity and increase vulnerability to oxidative stress during chemical exposure?

The GSTP1 rs1695 polymorphism, involving an A-to-G transition that results in an isoleucine-to-valine substitution (Ile105Val), significantly alters the detoxification capacity of the Glutathione S-transferase P1 enzyme. For individuals with the AG (heterozygous) variant, this translates to a measurable reduction in the ability to neutralize electrophilic toxins compared to those with the wild-type AA genotype.

Enzymatic activity and kinetics

Biochemical research indicates that the Val105 substitution modifies the hydrophobic binding pocket (H-site) of the enzyme, which is critical for substrate interaction.

• Reduced Affinity: This structural change increases the Michaelis constant (Km) from approximately 0.33 mM in the wild-type to 1.15 mM in variant allozymes, signaling a significantly lower affinity for substrates.
• Decreased Efficiency: The overall catalytic efficiency (kcat/Km) is reduced by an estimated 50% to 70% in variant genotypes. The AG genotype represents an intermediate phenotype, operating at a lower capacity than the AA genotype but higher than the GG variant.

Mechanistic impact on detoxification

GSTP1 is a primary phase II enzyme responsible for conjugating reduced glutathione (GSH) to reactive, electrophilic intermediates, such as polycyclic aromatic hydrocarbon (PAH) diol epoxides and various products of lipid peroxidation.

• Prolonged Exposure: When conjugation is slowed due to reduced enzymatic activity, these reactive species persist in the cellular environment.
• Cellular Damage: The delayed clearance allows these intermediates to bind to cellular macromolecules, forming harmful DNA adducts and damaging proteins or lipids.

Vulnerability to oxidative stress

The reduction in detoxification efficiency directly heightens physiological vulnerability during chemical exposure.

• Biomarker Elevation: Clinical studies demonstrate that carriers of the G allele exhibit significantly higher biomarkers of oxidative damage, such as 8-OHdG (DNA oxidation) and malondialdehyde (MDA), following exposure to environmental pollutants like tobacco smoke, PM2.5, or pesticides.
• Reduced Antioxidant Capacity: This genetic profile results in a diminished total antioxidant capacity when the body is challenged by xenobiotics or industrial chemicals.

Bottom line

The GSTP1 rs1695 AG variant reduces enzyme activity by approximately 50-70%, impairing the clearance of reactive intermediates and directly increasing cellular vulnerability to oxidative stress during chemical or environmental exposure.